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Abstract
In non-obese diabetic (NOD) mice that spontaneously develop autoimmune diabetes, plasmacytoid dendritic cells (pDCs)
have a diabetes-promoting role through IFN-a production on one hand, while a diabetes-inhibiting role through
indoleamine 2,3-dioxygenase (IDO) production on the other. Little is known about the kinetics and phenotype of pDCs in
the NOD pancreas during the development of autoimmune diabetes. While para/peri-insular accumulation of conventional
dendritic cells (cDCs) could be observed from 4 weeks of age onwards in NOD mice, pDCs only started to accumulate
around the islets of Langerhans from 10 weeks onwards, which is concomitant with the influx of lymphocytes. NOD
pancreatic pDCs showed a tolerogenic phenotype as assessed by their high expression of IDO and non-detectable levels of
IFN-a and MxA. Furthermore, expression of the pDC-attracting chemokines CXCL10 and CXCL12 was significantly increased
in the NOD pancreas at 10 weeks and the circulating pDC numbers were increased at 4 and 10 weeks. Our data suggest that
a simultaneous accumulation of IDO+ pDCs and lymphocytes in the pancreas in 10 weeks old NOD mice, which may reflect
both an immunogenic influx of T cells as well as a tolerogenic attempt to control these immunogenic T cells.
Citation: Welzen-Coppens JMC, van Helden-Meeuwsen CG, Leenen PJM, Drexhage HA, Versnel MA (2013) The Kinetics of Plasmacytoid Dendritic Cell
Accumulation in the Pancreas of the NOD Mouse during the Early Phases of Insulitis. PLoS ONE 8(1): e55071. doi:10.1371/journal.pone.0055071
Editor: Hossam M. Ashour, Wayne State University, United States of America
Received October 8, 2012; Accepted December 18, 2012; Published January 25, 2013
Copyright:  2013 Welzen-Coppens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors would like to thank the Juvenile Diabetes Research Foundation for supporting this study, grant number 5-2006-31 (http://www.jdrf.org/).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.coppens@erasmusmc.nl
Introduction
The nonobese diabetic (NOD) mouse model is a widely used
animal model of type 1 diabetes (T1D) [1] and characteristically
develops lymphocyte accumulations around the islets of Lang-
erhans from the age of 10 weeks onwards [2,3]. These cellular
accumulations subsequently progress to infiltration of the islets
and finally destruction of the insulin-producing beta cells. Prior
to the lymphocyte accumulation, an increased influx of
conventional dendritic cells (cDCs) into the NOD pancreas
from 4 weeks onwards can be observed and these cDCs
concentrate in and around the islets [4,5]. Previously, we
showed in a depletion study using clodronate-loaded liposomes,
that these early accumulating mDCs are essential for the
recruitment of lymphocytes into the NOD pancreas [6]. A study
by Saxena et al. [7] using conditional knock-out mice confirmed
these observations and showed that an early temporal depletion
of mDCs totally abrogated the development of insulitis and
diabetes in the NOD mouse model.
In addition to mDCs, distinct and vital roles for pDCs have also
been described to be important in the development and pro-
gression of diabetes [8,9]. In mice pDCs are characterized as
CD11b2CD11clowB220+PDCA-1+Siglec-H+ cells, and these cells
express the chemokine receptors CCR5,27, CXCR3 and 24 [9].
pDCs are classically known as important mediators of antiviral
immunity through their ability to produce large quantities of type I
interferons (IFN) upon viral infection and stimulation of the
appropriate toll-like receptors (TLRs) [8]. While virally activated
pDCs act as immunogenic cells, resting or alternatively activated
pDCs have been described to have tolerogenic activity [10,11].
Interestingly, an aberrant chronic pDC activation and secretion of
type I IFN has been found in systemic autoimmune diseases such
as systemic lupus erythematosus (SLE) and Sjo¨gren’s Syndrome,
and it is thought to play an important role in the pathogenesis of
these systemic autoimmune disorders [12–15].
In the development of autoimmune diabetes in NOD mice,
both a pathogenic and tolerogenic role for pDCs has been
described. pDCs were found to be pathogenic and contribute to
disease development through IFN-a production on one hand
[7,16,17], while depletion of pDCs on the other led to an
acceleration of insulitis and a loss of local indoleamine 2,3-
dioxygenase (IDO) [7,18]. It has been suggested that the
aggressiveness of the NOD insulitis is controlled by local
tolerogenic pDCs and production of IDO, which could induce
deletion of self-reactive cells by depleting the cells of tryptophan
or could stimulate the development of regulatory T cells
through the production of kynurenine products [19]. pDCs
could also act in a tolerogenic manner through interaction
between the programmed death ligand 1 (PD-L1) on pDCs and
PD-1 on T cells, which delivers inhibitory signals to T cells
[20]. However, whether this pathway plays a role in the
tolerogenic function of pDCs in NOD autoimmune diabetes has
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not yet been addressed. In fact, little is known about the kinetics
of pDC accumulation in the NOD pancreas during the
spontaneous development of the autoimmune insulitis process.
Here we investigated the presence and localization of pDCs in
the NOD pancreas during the early phases of insulitis (4 and 10
weeks). We analyzed their expression of IDO and PD-L1 as well as
local IFN production, both by protein expression and by induction
of the IFN-inducible gene myxovirus (influenza) resistance A
(MxA). In addition, we studied the pancreatic expression of
chemokines that are important for the attraction of pDCs from the
circulation and enumerated pDCs in the circulation of the NOD
mouse in the early phases of the insulitis process.
Materials and Methods
Animals
C57BL/6 and NOD/shiLTj female mice were obtained from
Charles River Laboratories (Maastricht, The Netherlands) and
NOR/LTj mice from the Jackson Laboratory (Bar Harbor, ME,
USA). Mice of 4, 10 and 20 weeks of age were used and housed
under specific pathogen-free conditions.
Ethics Statement
Sampling of the mice was approved by the Animal Experiments
committee of the Erasmus MC (Dierexperimentencommissie
(DEC), which is the ethical committee installed and officially
recognized as required by the Dutch Law on Experimental
Animals, the Dutch analogue for the IACUC). The approval
number is: DEC#2334, dated June 15, 2011. The study was
conducted in compliance with all relevant Dutch laws and in
agreement with international and scientific standards and guide-
lines.
Immunohistochemistry
Cryostat sections (6 mm) of pancreases of C57BL/6, NOR and
NOD mice were prepared and fixed with cold methanol and
acetone. Slides were incubated with rat-anti-Siglec-H (both
eBiosciences, San Diego, CA, USA) or rat-anti-IDO (Biolegend,
San Diego, CA, USA) followed by rabbit-anti-rat-PO (DAKO,
Glostrup, Denmark). Subsequently, slides were incubated with
Nickel-DAB and counterstained with nuclear fast red (both Sigma
Aldrich, St. Louis, MO, USA), followed by mounting in Entallan
(Merck, Darmstadt, Germany). Insulitis was evaluated by the
analysis of at least 50 islets according the following scale: 0, no
infiltrating cells; 1, few infiltrating cells peri-insular; 2, large
numbers of infiltrating cells around the islet and 3, large numbers
of infiltrating cells in the islet.
Immunofluorescence
Cryostat sections (6 mm) of pancreases of C57BL/6 and NOD
mice of were prepared and fixed with cold methanol and acetone.
Slides were incubated with rat-anti-IDO followed by goat-anti-rat-
TexasRed (Southern Biotechnology Associates Inc., Birmingham,
AL, USA) and rat-anti-Siglec-H-FITC (eBiosciences). Finally,
slides were mounted in Vectashield with DAPI (Vector Labora-
tories Inc., Burlingame, CA, USA).
Preparation of Cell Suspensions
Pancreases were isolated after a cardiac perfusion and cut into
small pieces and digested with collagenase type 1 (1 mg/ml),
hyaluronidase (2 mg/ml) (both Sigma Aldrich, St. Louis, MO,
USA) and DNAse I (0.3 mg/ml) (Roche Diagnostics, Almere, The
Netherlands) for 40 minutes at 37uC. Subsequently, cells were
flushed through a 70 mm filter and washed. Blood was collected in
EDTA tubes after a cardiac punction. Erythrocytes were lysed
with NH4Cl buffer and cells washed with PBS. All cells were
resuspended in PBS containing 0.1% BSA followed by flow
cytometric staining.
Flow Cytometry
Single-cell suspensions from pancreas were labeled with CD45
beads (Miltenyi, Leiden, The Netherlands) and CD45+ cells were
sorted using AutoMACS (Miltenyi) and labeled with mAbs. Single-
cell suspensions from blood were labeled with mAbs. Antibodies
used were B220-Pacific Blue, CCR5-PE, CCR7-PE-Cy7,
CXCR3-PE, CXCR4-APC, CD11b-APC-Cy7, CD80-PE-Cy5,
CD86-APC, PDCA-1-FITC and PD-L1-PE (all eBiosciences, San
Diego, CA, USA). Afterwards cells were washed and resuspended
in 0.1% BSA/0.5% paraformaldehyde, followed by analysis on
a FACS Canto HTSII (Becton Dickinson) flow cytometer and
FACS Diva and Flowjo software.
Protein Expression Determination
Pancreas lysates of C57BL/6, NOR and NOD mice were
prepared by homogenization of the pancreas in ice-cold PBS
supplemented with protease inhibitor cocktail (Life Technologies,
Paisley, UK). The lysates were sonicated twice for 30 seconds and
centrifuged at 1000 g at 4uC for 10 minutes. The supernatant was
collected and stored at 280uC. The protein concentration in the
pancreas lysates was determined using the Bradford method (Bio-
rad Laboratories GmbH, Mu¨nchen, Germany).
The pancreas lysates were tested for CXCL10 protein
expression using a cytometric bead array according to the
manufacturer’s protocol (eBiosciences). Briefly, a mixture of beads
coated with antibodies against CXCL10 was incubated with the
lysate or standard mixture. A biotin-conjugated second antibody
mixture was added followed by streptavidin-PE. Samples were
analyzed using a FACS Canto HTSII (Becton Dickinson) and
FlowCytomix Pro Software (eBiosciences). CXCL9, 211 and 212
(R&D Systems, Minneapolis, MN, USA) and IFN-a (PBL In-
terferon source) protein expression were determined using ELISA
kits according to the manufacturers protocol.
Statistical Analysis
Data were analyzed by Mann-Whitney U test for unpaired data.
All analyses were carried out using SPSS software (SPSS Inc.,
Chicago, IL, USA) and considered statistically significant if
p,0.05.
Results
pDCs Accumulate Around the Islets in the NOD Pancreas
Concomitant with Lymphocytes, but Later than mDCs
The localization of mDCs and pDCs in the pancreas of NOD,
C57BL/6, and nonobese diabetic resistant (NOR) mice of 4 and
10 weeks was studied by immunohistochemistry. The NOR mouse
is a NOD-related MHC-syngeneic strain, and often used as
a control strain for the NOD mouse model. NOR mice do not
develop diabetes and only have a mild lymphocytic peri-insulitis
[21].
From 4 weeks onwards CD11c+ mDCs were observed to
accumulate around the islets in the NOD pancreas (Fig. 1A and
B). The peri-islet accumulation of CD11c+ mDCs was also
observed in the NOR pancreas, although at reduced numbers.
Siglec-H+ pDCs were detectable in the exocrine pancreas of
NOD mice from 4 weeks onwards, but significant differences
were not detected between NOD and control strains. At 10
weeks the lymphocytic para/peri-insulitis had started in the
Kinetics of pDC Accumulation in NOD Pancreas
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e55071
NOD mouse, at that time mDCs had become more numerous
and pDCs also had started to accumulate at the islet edges
(Fig. 1A). The number of Siglec-H+ pDCs was significantly
higher in the NOD pancreas as compared to NOR and
C57BL/6 at 10 and 20 weeks (Fig. 1C). In the NOD pancreas
the levels of mDCs and pDCs at 20 weeks were not significantly
different from the NOD levels at 10 weeks.
In addition to the immunohistochemistry, flow cytometry was
performed on sorted CD45+ cells from the pancreas of 4 and 10
week old C57BL/6, NOR and NOD mice. As Siglec-H was not
detectable after the pancreatic digestion (data not shown), pDCs
were identified by PDCA-1 staining. No differences in
CD11b2PDCA-1+ pDCs were observed between the strains at 4
weeks of age (Fig. 2A–C). However, at 10 weeks both the
percentage and absolute number of CD11b2PDCA-1+ pDCs was
significantly increased in NODmice compared to controls (Fig. 2A,
D and E). All strains showed similar expression of B220 in the
CD11b2PDCA-1+ pDC population (Fig. 2F), but CD80 and
CD86 were significantly increased in NOD mice (Fig. 2F–H),
suggesting increased level of activation.
Enhanced IDO, but Decreased PD-L1 and Absent IFN-
a Expression of NOD Pancreatic pDCs
As NOD pancreatic pDCs expressed increased levels of co-
stimulatory molecules, immunohistochemical analysis of both
tolerogenic and activational markers was performed. In 4 week
old NOD mice low numbers of IDO+ cells were detected near
blood vessels in the exocrine pancreas. From 10 weeks onwards,
when pDCs were found to accumulate at the islet edges, IDO+
cells were also detected both around and in the islets (Fig. 3A).
Immunofluorescent analysis confirmed that IDO+ cells were
Siglec-H+ pDCs (Fig. 3B). In the pancreas of C57BL/6 and
NOR mice IDO+ cells were not detected (data not shown). In
contrast, NOD pancreatic pDCs showed significantly decreased
expression of the tolerogenic ligand PD-L1 compared to control
strains (Fig. 3C and D). As pDCs are important producers of high
amounts of IFN-a upon TLR activation by viruses and immune
complexes, IFN-a expression in the pancreas was analyzed. No
expression of IFN-a protein and the IFN-induced gene MxA
mRNA was detected in the pancreas of all mouse strains at 4, 10
and 20 weeks of age (data not shown).
Figure 1. Accumulation of mDCs and pDCs in the NOD pancreas. The localization of mDCs and pDCs in the C57BL/6, NOR and NOD pancreas
at the age of 4, 10 and 20 weeks was determined by immunohistochemical detection. Pictures show CD11c and Siglec-H expression in the pancreas
of mice from 4, 10 and 20 weeks of age, magnification 200x (A). Bar graphs represent the mean insulitis score of CD11c+ (B) and Siglec-H+ cells (C) in
the pancreas. Data are presented as average+SEM, n = 5 mice, * p,0.04, ** p,0.01, *** p,0.001 as determined by the unpaired Mann-Whitney U test.
doi:10.1371/journal.pone.0055071.g001
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Figure 2. Increased pDC numbers in the NOD pancreas at 10 weeks of age. The presence of pDCs in the C57BL/6, NOR and NOD pancreas at
the age of 4 and 10 weeks was determined by flow cytometry. Dot plots show the CD11b and PDCA-1 expression on sorted CD45+ cells from the
pancreas (A). Bar graphs represent the percentage and the absolute number of CD11b2PDCA-1+ cells in the pancreas at 4 (B–C) and 10 weeks (D–E).
Histograms represent the B220, CD80 and CD86 expression on pDCs (CD11b2PDCA-1+ cells) in the pancreas of 10 weeks (F). Bar graphs represent the
geometric MFI of CD80 (G) and CD86 (H) on pDCs. Data are presented as average+SEM, n = 5–6 mice, *p,0.04, ** p,0.01 as determined by the
unpaired Mann-Whitney U test.
doi:10.1371/journal.pone.0055071.g002
Figure 3. Enhanced IDO and a decreased PD-L1 expression in NOD pancreas pDCs. Pictures show the immunohistochemical detection of
IDO in the pancreas of NOD mice at 4, 10 and 20 weeks of age, magnification 200x (A). The pancreas of NOD mice was stained for Siglec-H (green),
IDO (red) and DAPI (blue) by immunofluorescence, magnification 400x (B). Histogram represents the PD-L1 expression on pDCs (CD11b2PDCA-1+
cells) in the pancreas of C57BL/6, NOR and NOD mice of 10 weeks of age (C). Bar graph represents the geometric MFI of PD-L1 on pDCs (D). Data are
presented as average+SEM, n = 5 mice, * p,0.04, ** p,0.01 as determined by the unpaired Mann-Whitney U test.
doi:10.1371/journal.pone.0055071.g003
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High Expression of CXCL10 and CXCL12 in the NOD
Pancreas at the Time of pDC Accumulation
To investigate which chemokines and chemokine receptors
might be important for the attraction of the pDCs, flow cytometry
was performed on pancreatic pDCs. pDCs in the pancreas of all
strains expressed similar levels of CXCR3 (Fig. 4A), but NOD
pDCs expressed increased levels of CXCR4 (Fig. 4A and B). No
expression of CCR5 or CCR7 was detected in all three strains
(data not shown).
As pancreatic pDCs expressed CXCR3 and CXCR4, the
protein expression of their ligands CXCL9, CXCL10, CXCL11
(for CXCR3) and CXCL12 (for CXCR4) was assessed. CXCL9
and CXCL12 protein levels were significantly increased in the
NOD pancreas at 4 weeks of age (Fig. 4C and E), although
CXCL9 levels did not reach statistical significance at 10 weeks of
age. CXCL10 protein expression levels were only significantly
increased in the NOD pancreas at 10 weeks of age (Fig. 4D) and
no significant differences were found in the CXCL11 protein
expression between the strains (data not shown).
Increased Numbers of pDCs in the Circulation of NOD
Mice
In peripheral blood, both an increase and reduction in the
numbers of circulating pDCs have been described in the various
phases of type 1 diabetes (T1D) development in humans
[18,22,23]. Numbers of pDCs in the blood of C57BL/6, NOR
and NOD mice were studied by flow cytometry at 4 and 10 weeks
of age. At both ages the percentage of CD11b2PDCA-1+ pDCs in
the blood of NOD and NOR mice was significantly increased as
compared to C57BL/6 (Fig. 5A–C). Furthermore, NOD mice
showed an increased percentage of pDCs compared to NOR mice
at 10 weeks of age (Fig. 5A and C). pDCs were B220+, CXCR3+,
CXCR4+ and PD-L1low, expressed at similar levels in all 3 strains
(Fig. 5D). However, the NOD and NOR pDCs expressed
significantly higher levels of the co-stimulatory molecules CD80
and CD86 at 4 (data not shown) and 10 weeks of age compared to
C57BL/6 mice (Fig. 5D–F), suggesting increased activation state.
Moreover, circulating pDCs in NOD mice also expressed
significantly higher levels of CD80 and CD86 compared to
NOR mice at 4 (data not shown) and 10 weeks of age (Fig. 5D–F).
Discussion
This study shows that pDCs with a tolerogenic IDO+ profile
accumulate at the islet edges in the NOD pancreas at 10 weeks of
age. This is at the same time that lymphocytes can be observed to
accumulate around the islets [2,3]. In contrast, the accumulation
of immunogenic disease-promoting mDCs occurred earlier from 4
weeks of age onwards. pDCs in the NOD pancreas have a partial
tolerogenic profile by expressing IDO, although the PD-L1
expression was lower. Furthermore, no expression of IFN-a and
the IFN-induced gene MxA is detected in the NOD pancreas. The
pDC increase is accompanied by an increased expression of
CXCL10 and 212 in the NOD pancreas.
Saxena et al. [7] described a role for IDO in the down-
regulation of the NOD insulitis using an IDO inhibitor, but the
actual IDO-producing cells were not identified. Here, we show
that pDCs in the NOD pancreas express IDO, identifying
a potential local tolerogenic role for these cells. However, pDCs
have also been implicated in a disease-promoting role in the NOD
mouse: IFN-a+ pDCs were increased in the pancreas-draining
lymph nodes (pLNs) of 4 week old NOD mice and an antibody to
the IFN-a receptor was able to halt the diabetogenic process
[24,25]. In our hands we did not detect significant numbers of
Figure 4. Expression of pDC receptors and chemokines in the pancreas. Histograms represent the CXCR3 and CXCR4 expression on pDCs
(CD11b2PDCA-1+ cells) in the pancreas of 10 weeks of age (A). Bar graph represents the geometric MFI of CXCR4 on pDCs in the pancreas of 10
weeks of age (B). Bar graphs represent the protein level of CXCL9 (C57BL/6 and NOD), CXCL10 and CXCL12 (C57BL/6, NOR and NOD) in pancreas
lysates of 4 and 10 weeks (C-E). Data are presented as average+SEM, n= 5–10 mice, * p,0.04, ** p,0.01 as determined by the unpaired Mann-
Whitney U test.
doi:10.1371/journal.pone.0055071.g004
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pDCs in the NOD pancreas as early as 4 weeks, although we did
not analyze pLNs. Furthermore, levels of IFN-a and the
interferon-inducible gene MxA were not detectable in both
NOD and control mouse strains. Our data would therefore not
support an immunogenic function for pancreatic pDCs in the
NOD mouse and we favour a tolerogenic role for pancreatic
pDCs. Collectively, the literature data and our findings suggest
that pDCs in the pLNs early in the process have a different and
opposite function (i.e. disease-promoting) as compared to those
infiltrating the pancreas at later stages of the disease (disease-
inhibiting). While IDO-expressing pDCs were only found in the
NOD pancreas, we found a reduced expression level of PD-L1 on
these cells compared to pancreatic pDCs in control strains.
Interestingly, endocrine cells of inflamed islets of 10 week old pre-
diabetic NOD mice also express PD-L1 (but not PD-L2) at 10
weeks of age, and blocking PD-L1 increased insulitis severity and
diabetes development in NOD mice [26]. This suggests that PD-
L1 may be involved in mediating apoptosis of autoreactive effector
T cells in the peri-insulitis, but it remains to be investigated
whether this is due to expression of PD-L1 by tolerogenic pDCs or
by endocrine cells under immune attack.
A limitation of our study is that the number of pDCs in the
pancreas was too low to perform functional studies. Such studies
would have strengthened our observations. Another limitation is
that the digestion method for the pancreas influenced the
expression of Siglec-H. Siglec-H is selectively expressed on pDCs
Figure 5. Increased percentage of pDCs in blood of NOR and NOD mice. The presence of pDCs in the blood of C57BL/6, NOD and NOR of 4
and 10 weeks was determined by flow cytometry. Dot plots show the CD11b and PDCA-1 expression (A). Bar graphs represent the percentage of
pDCs (CD11b2PDCA-1+ cells) at 4 weeks (B) and 10 weeks (C). Histograms represent the B220, CD80, CD86, CXCR3, CXCR4 and PD-L1 expression on
pDCs in the pancreas of 10 weeks (D). Bar graphs represent the MFI of CD80 (E) and CD86 expression (F) on pDCs at 10 weeks. Data are presented as
average+SEM, n = 4–10 mice, * p,0.04, ** p,0.01, *** p,0.001 as determined by the unpaired Mann-Whitney U test.
doi:10.1371/journal.pone.0055071.g005
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and certain macrophage subsets in the spleen and considered the
best marker for pDCs [27,28]. Since Siglec-H could not be used
for the flow cytometric analysis we used PDCA-1 in combination
with other phenotypic markers, like CD11b and B220, to
distinguish pDCs. PDCA-1, also known as bone marrow stromal
antigen-2, is selectively expressed on pDCs, but is also up
regulated on other cell types upon type I IFN or IFN-c stimulation
[29]. Despite the reduced specificity of PDCA-1, both immuno-
histochemistry and flow cytometric analysis suggested an accu-
mulation of pDCs in the NOD pancreas at the time of lymphocyte
insulitis, but at a later stage than mDCs.
The mean insulitis score of Siglec-H+ pDCs was higher as
compared to CD11c+ mDCs likely due to the fact that pDCs
express low levels of CD11c and the limited sensitivity of this
staining.
With regard to the chemokines attracting pDCs, recent studies
showed that the expression of CXCL10 alone was not sufficient for
pDC recruitment, but that the co-expression of CXCL10 and
CXCL12 synergistically was required to induce pDC migration
[30,31]. We observed that the expression of both CXCL10 and
CXCL12 was elevated in the NOD pancreas at 10 weeks of age.
In addition, the receptor for CXCL12, CXCR4, was significantly
increased on pDCs in the NOD pancreas and CXCR3, the
receptor for CXCL10, was normally expressed. These findings are
supportive of synergistic function of CXCL10 and CXCL12 in the
recruitment and retention of pDCs in the NOD pancreas.
Moreover, in the pancreas of NOR mice CXCL10 and CXCL12
were not increased and pDC infiltration was not observed. It has
been shown that beta cells express CXCL10 during the insulitis in
LCMV-infected mice [32] and purified human and rat islet cells
have been found to produce CXCL10 upon stimulation with IFN-
c or IL-1b [33]. It is therefore likely that the endocrine cells are the
source of these pDC-attracting chemokines, but this needs further
investigations.
Several reports have shown reduced pDC numbers in the
circulation of patients with recent onset T1D (within 3 months) as
well as in patients with long standing T1D (more than 5 years)
[22,23]. Interestingly, a recent study showed an increased
frequency of pDCs in the blood of T1D patients at the time of
diagnosis, which declined after disease onset [18]. This observation
is in line with our data showing an increased pDC number in the
blood of NOD mice with active insulitis and points to the putative
importance of distinguishing the different phases of disease
development in humans and animal models with regard to pDC
frequencies in the circulation. Perhaps high numbers of circulating
pDCs might be an early sign of an existing (pre-)diabetic insulitis
process.
In summary, our present and past studies on the kinetics of the
accumulation of the various subsets of DCs in the NOD pancreas
during the development of diabetes reveal the following pattern of
accumulation:
1) From 4 weeks onwards mDCs start to accumulate in the
NOD pancreas. It is our hypothesis that this accumulation of
mDCs is (at least in part) due to an aberrant proliferation of
local pancreatic precursors for mDCs [34]. Retention of
activated and maturing mDC population in the pancreas
might be due to an aberrant expression in the pancreas of the
lymphoid tissue-specific CCR7 ligands CCL19 and CCL21,
as described previously by us [35]. These mDCs are local
drivers of the immunogenic effector response towards islet
antigens. In addition, a recent study used magnetic resonance
imaging (MRI) to visualize local effects of pancreatic-islet
inflammation to predict the onset of diabetes in NOD mice
[36]. They show that autoimmune diabetes is set at an early
age in these mice. In pLNs, mDCs but also IFN-a-producing
pDCs are drivers of the immunogenic effector response
towards islet antigens.
2) From 10 weeks onwards pDCs and lymphocytes accumulate
in the NOD pancreas, possibly attracted by CXCL10 and
CXCL12 expression. The infiltrating pDCs express IDO and
are meant to dampen the insulitis development in an attempt
to halt the insulitis process.
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